InnoCan PharmaHAM:IP40 -5.32%59 PS Ratio is 0.28 as of Jul. 01, 2026, which is 96% below its 10-year median of 6.26. GuruFocus rates HAM:IP40 with a GF Score™ of 59/100 and a GF Value™ of €9.22 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,933 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 79.77% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, InnoCan Pharma's share price is €1.335.
InnoCan Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €4.84. Hence, InnoCan Pharma's PS Ratio for today is 0.28.
Good Sign:
InnoCan Pharma Corp stock PS Ratio (=0.33) is close to 10-year low of 0.33.
The historical rank and industry rank for InnoCan Pharma's PS Ratio or its related term are showing as below:
HAM:IP40'
s PS Ratio Range Over the Past 10 Years
Min: 0.31 Med: 6.26 Max: 10616.67
Current: 0.31
During the past 8 years, InnoCan Pharma's highest PS Ratio was 10616.67. The lowest was 0.31. And the median was 6.26.
HAM:IP40's PS Ratio is ranked better than 79.77% of 1933
companies
in the Consumer Packaged Goods industry
Industry Median: 0.85
vs HAM:IP40: 0.31
InnoCan Pharma Corp revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of InnoCan Pharma was -20.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 108.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 373.70% per year.
During the past 8 years, InnoCan Pharma's highest 3-Year average Revenue per Share Growth Rate was 950.30% per year. The lowest was 108.20% per year. And the median was 410.90% per year.
Back to Basics: PS Ratio
InnoCan Pharma (HAM:IP40) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
InnoCan Pharma PS Ratio Related Terms
InnoCan Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
InnoCan Pharma's Share Price of today is €1.335. InnoCan Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
InnoCan Pharma (HAM:IP40) has a PS Ratio of 0.28 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on InnoCan Pharma and its competitors. This is 96% below median its historical median of 6.26. Over the past decade, InnoCan Pharma's PS Ratio has ranged from 0.31 to 10,616.67. According to the industry distribution chart, InnoCan Pharma ranks #391 out of 1933 companies in the Consumer Packaged Goods industry, placing it in the top 20.2%.
Is InnoCan Pharma's PS Ratio too high?
InnoCan Pharma's current PS Ratio of 0.28 is 96% below median its 10-year median of 6.26. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 10,616.67. The Consumer Packaged Goods industry median PS Ratio is 0.85. InnoCan Pharma's value of 0.28 is 67.1% below this industry median. Based on the distribution chart, InnoCan Pharma ranks #391 out of 1933 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's PS Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #391 out of 1933 companies for PS Ratio. This places InnoCan Pharma in the top 20% of its industry — outperforming the majority of peers. The industry median PS Ratio is 0.85. InnoCan Pharma's value of 0.28 is 67.1% below this benchmark. Historically, InnoCan Pharma's own PS Ratio has ranged from 0.31 to 10,616.67 over the past decade. While the company's 10-year median is 6.26 vs. the industry median of 0.85, InnoCan Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Consumer Packaged Goods company?
The median PS Ratio among Consumer Packaged Goods companies is 0.85, based on 1,933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current PS Ratio of 0.28 is 67.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median PS Ratio is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current PS Ratio is 0.28, which is 96% below median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.22, compared to a current price of €1.34 — trading 85.5% below its estimated fair value. The current PS Ratio is 0.28, which is 96% below median its 10-year median of 6.26 and 67.1% below the Consumer Packaged Goods industry median of 0.85. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current PS Ratio is 0.28 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.34 is trading 85.5% below its estimated GF Value™ of €9.22.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
PS Ratio: 0.28 (96% below median its 10-year median of 6.26)
GF Value™: €9.22 vs. price of €1.34 (85.5% below fair value)
Industry Position: 67.1% below the Consumer Packaged Goods median (#391 of 1933)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
59GF Score
Get the complete analysis for HAM:IP40
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
